IPAD-DB ID | C00650 |
Name | Salidroside |
Category | Natural compounds |
2D Structure |
|
3D Structure | |
Molecular Formula | C 1 4 H 2 0 O 7 |
Molecular Weight | 300.30g/mol |
IUPAC Name | (2R, 3S, 4S, 5R, 6R)-2-(hydroxymethyl)-6-[2-(4-hydroxyphenyl)ethoxy]oxane-3, 4, 5-triol |
InChI | InChI=1S/C14H20O7/c15-7-10-11(17)12(18)13(19)14(21-10)20-6-5-8-1-3-9(16)4-2-8/h1-4, 10-19H, 5-7H2/t10-, 11-, 12+, 13-, 14-/m1/s1 |
InChIKey | ILRCGYURZSFMEG-RKQHYHRCSA-N |
Canonical SMILES | C1=CC(=CC=C1CCOC2C(C(C(C(O2)CO)O)O)O)O |
PubChem CID | 159278 |
DrugBank Accession Number | - |
CAS Registry Number | 10338-51-9 |
Molecular Weight(Computed by SwissADME) | 300.3 |
Hac(Computed by SwissADME) | 21 |
Volume(Computed by ADMETlab 2.0) | 287.21 |
Density(Computed by ADMETlab 2.0) | 1.045 |
nRing(Computed by ADMETlab 2.0) | 2 |
MaxRing(Computed by ADMETlab 2.0) | 6 |
nHet(Computed by ADMETlab 2.0) | 7 |
fChar(Computed by ADMETlab 2.0) | 0 |
nRig(Computed by ADMETlab 2.0) | 12 |
Flexibility(Computed by ADMETlab 2.0) | 0.417 |
Stero Centers(Computed by ADMETlab 2.0) | 5 |
LogS(Computed by ADMETlab 2.0) | -0.902 |
LogD(Computed by ADMETlab 2.0) | -0.292 |
logP(Computed by ADMETlab 2.0) | -1.226 |
TPSA(Computed by SwissADME) | 119.61 |
Hbond Acceptor(Computed by SwissADME) | 7 |
Hbond Donor(Computed by SwissADME) | 5 |
Rotatable Bonds(Computed by SwissADME) | 5 |
GI Absorption(Computed by SwissADME) | High |
BBB(blood-brain barrier) Permeant(Computed by SwissADME) | No |
P-gp Substrate(Computed by SwissADME) | No |
CYP1A2 Inhibitor(Computed by SwissADME) | No |
CYP2C19 Inhibitor(Computed by SwissADME) | No |
CYP2C9 Inhibitor(Computed by SwissADME) | No |
CYP2D6 Inhibitor(Computed by SwissADME) | No |
CYP3A4 Inhibitor(Computed by SwissADME) | No |
log Kp(Skin Permeation)(Computed by SwissADME) | -8.88 |
Lipinski(Computed by SwissADME) | 0 |
Ghose(Computed by SwissADME) | 1 |
Veber(Computed by SwissADME) | 0 |
Egan(Computed by SwissADME) | 0 |
Muegge(Computed by SwissADME) | 0 |
Bioavailability Score(Computed by SwissADME) | 0.55 |